Floseal
PreclinicalSmall molecule
Floseal is one of 8 small molecule programs targeting Epistaxis. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Epistaxis
#DrugCompanyPhaseTrials
1Avastin
RocheApproved
Cyklokapron
JJ Molner
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Bactroban
PPadagis LLC
Approved
Silver Nitrate
MMansoura University Hospital
Preclinical
Trichloroacetic Acid
IIndonesia University
Preclinical
Floseal
UUnity Health Toronto
Preclinical
Thrombin JMI
UUniversity of Kansas Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Total Knee Arthroplasty3 trials
Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty
Completed·—·Phase 4·NCT03328832·70 enrolled
Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty
Unknown status·—·Phase 4·NCT02865174·90 enrolled
Epistaxis2 trials
Bleeding1 trial
Total Hip Arthroplasty1 trial
Blood-saving Effect of Combined Intravenous Tranexamic Acid With Topical Floseal® Application Total Hip Arthroplasty
Unknown status·—·Phase 4·NCT03623789·90 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Floseal. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUnity Health Toronto